Godavari Biorefineries Secures European Patent for Novel Anti-Cancer Drug Composition with Enhanced Bioavailability
核心洞察
Godavari Biorefineries (搜索) has been granted a patent by the European Patent Office for a pharmaceutical composition combining novel anti-cancer compounds with a solubilising agent, effective July 15, 2026.
The patented formulation addresses the challenge of oral delivery by improving solubility and bioavailability of active therapeutic ingredients targeting breast and prostate cancers.
The grant provides exclusive rights across designated European Contracting States, strengthening the company's oncology IP portfolio alongside existing patents in China, Spain, UK, EU member states, and Japan.
Godavari Biorefineries (搜索) Limited has secured a patent grant from the European Patent Office (EPO) for a pharmaceutical composition comprising novel anti-cancer compounds combined with a solubilising agent, the company disclosed in a regulatory filing on August 11, 2026. The patent, numbered EP4404920 and granted on July 15, 2026, protects a formulation process designed to enhance the solubility and bioavailability of active therapeutic ingredients—a critical challenge in delivering potent anti-cancer agents through oral administration.
The patented composition specifically targets breast and prostate cancers, two of the most prevalent malignancies worldwide. By incorporating a solubilising agent, the formulation aims to improve the therapeutic potential of the drug candidates, potentially overcoming absorption barriers that have historically limited the clinical utility of certain anti-cancer compounds.
Patent Details and Strategic Significance
The European patent grant provides Godavari Biorefineries (搜索) with exclusive rights to the patented composition and its preparation process within designated European Contracting States. This intellectual property protection safeguards the company's innovation against infringement and supports potential future commercialization efforts across European markets.
The focus on bioavailability through solubilisation techniques underscores the company's commitment to advancing formulation science in oncology. The patent complements Godavari's growing global IP portfolio, which already includes patent recognition across China, Spain, the United Kingdom, multiple EU member states, and Japan—the latter secured for its breakthrough invention "5-Hydroxy-1,4-Naphthalenedione (搜索) for use in the treatment of cancer."
Regulatory Disclosure and Corporate Governance
Godavari Biorefineries (搜索) Limited disclosed the patent approval under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The disclosure was made to both the National Stock Exchange of India Limited and BSE Limited. Manoj Jain, Company Secretary and Compliance Officer (Membership No. F-7998), signed the communication confirming receipt of the Grant Certificate from the EPO.
Upcoming Investor Engagement
The company also announced it will hold a physical group meeting with analysts and institutional investors on August 12, 2026, as part of the Emkay Confluence-2026 event titled "India: Full Throttle Ahead." The engagement is structured as a group interaction rather than one-on-one sessions, ensuring equitable access to information for all participating analysts and investors.
Management emphasized that the discussion will rely exclusively on publicly available information, and no unpublished price-sensitive information (UPSI) is proposed to be shared or discussed during the session. This adherence to regulatory norms ensures compliance with insider trading prevention guidelines while maintaining transparency with market participants.
Broader Oncology Pipeline
Godavari Biorefineries (搜索) is developing novel cancer therapies while continuing to strengthen its global intellectual property portfolio. With a lead molecule undergoing clinical trials and patents secured across key international jurisdictions, the company continues to deepen its focus on translational research addressing some of the world's most pressing health challenges.
"We have always believed that our role is to use science to create a better world. Whether it is improving the health of our soil, supporting agriculture, advancing sustainable materials or discovering molecules that could shape the future of human health, the purpose remains the same," said Samir Somaiya, Chairman and Managing Director of Godavari Biorefineries (搜索). "Every patent we secure reflects the quality of our scientific research and strengthens our ability to build original molecules that can make a meaningful difference to society."